China’s medtech shake-up forces rethink on pricing, IP and innovation

A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

MedTech

UPC upholds injunction in Invisalign maker’s software dispute with rival

9 July 2026 China-headquartered Angelalign failed to convince UPC appellate judges to overturn a ban that affects its ability to offer orthodontic planning software in Europe with certain functionality.

MedTech

UPC revives patent, but timing sinks Guardant’s appeal

6 July 2026 The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.

MedTech

Could everyday hospital equipment be the next defence against counterfeit medicines?

23 February 2026 A new study suggests the equipment already found in hospitals worldwide could offer a front line against fake vaccines and insulin.